Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention

Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annual review of immunology 2020-04, Vol.38 (1), p.673-703
Hauptverfasser: Stephenson, Kathryn E, Wagh, Kshitij, Korber, Bette, Barouch, Dan H
Format: Artikel
Sprache:eng
Schlagworte:
bNAb
broadly neutralizing antibody
HIV-1
prevention
vaccine
viral diversity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 703
container_issue 1
container_start_page 673
container_title Annual review of immunology
container_volume 38
creator Stephenson, Kathryn E
Wagh, Kshitij
Korber, Bette
Barouch, Dan H
description Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.
doi_str_mv 10.1146/annurev-immunol-080219-023629
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7375352</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2395624959</sourcerecordid><originalsourceid>FETCH-LOGICAL-a560t-743105d9bc8f4fd265b4b41c8c1e98a236f150e1b9347c202e0d180f3b2ef5d23</originalsourceid><addsrcrecordid>eNqVkU9P3DAQxS3Uil0oX6HKpRIX0_G_JD5QaUFtWWkFHApXy3EcapTYi70B0U-PV1kQHHuaw7x572l-CH0jcEIIL79r78doH7EbhtGHHkMNlEgMlJVU7qE5EVxgRqv6E5pDxSgGUdMZOkjpHgAkY9U-mjHKOIiqnKPFrTbGeZsK7dviLAbd9s_FpR03Uffun_N3xcJvXBNalzVdiMXF8haT4jp3sHkR_Bf0udN9ske7eYhufv38c36BV1e_l-eLFdaihA2uOCMgWtmYuuNdS0vR8IYTUxtiZa1z_Y4IsKSRjFeGArXQkho61lDbiZayQ_Rj8l2PzWBbk9NzRbWObtDxWQXt1MeNd3_VXXhUFasEE1uD451BDA-jTRs1uGRs32tvw5gUZVKUlEshs_R0kpoYUoq2e4shoLYY1A6D2mFQEwY1Ycj3X993fbt-_XsWnE2CrY_us5OzT-k_U14AY9mgoQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2395624959</pqid></control><display><type>article</type><title>Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention</title><source>Annual Reviews Complete A-Z List</source><creator>Stephenson, Kathryn E ; Wagh, Kshitij ; Korber, Bette ; Barouch, Dan H</creator><creatorcontrib>Stephenson, Kathryn E ; Wagh, Kshitij ; Korber, Bette ; Barouch, Dan H</creatorcontrib><description>Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.</description><identifier>ISSN: 0732-0582</identifier><identifier>EISSN: 1545-3278</identifier><identifier>DOI: 10.1146/annurev-immunol-080219-023629</identifier><identifier>PMID: 32340576</identifier><language>eng</language><publisher>United States: Annual Reviews</publisher><subject>bNAb ; broadly neutralizing antibody ; HIV-1 ; prevention ; vaccine ; viral diversity</subject><ispartof>Annual review of immunology, 2020-04, Vol.38 (1), p.673-703</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a560t-743105d9bc8f4fd265b4b41c8c1e98a236f150e1b9347c202e0d180f3b2ef5d23</citedby><cites>FETCH-LOGICAL-a560t-743105d9bc8f4fd265b4b41c8c1e98a236f150e1b9347c202e0d180f3b2ef5d23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-immunol-080219-023629?crawler=true&amp;mimetype=application/pdf$$EPDF$$P50$$Gannualreviews$$H</linktopdf><linktohtml>$$Uhttps://www.annualreviews.org/content/journals/10.1146/annurev-immunol-080219-023629$$EHTML$$P50$$Gannualreviews$$H</linktohtml><link.rule.ids>70,230,314,776,780,881,4168,27901,27902,77997,77998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32340576$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stephenson, Kathryn E</creatorcontrib><creatorcontrib>Wagh, Kshitij</creatorcontrib><creatorcontrib>Korber, Bette</creatorcontrib><creatorcontrib>Barouch, Dan H</creatorcontrib><title>Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention</title><title>Annual review of immunology</title><addtitle>Annu Rev Immunol</addtitle><description>Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.</description><subject>bNAb</subject><subject>broadly neutralizing antibody</subject><subject>HIV-1</subject><subject>prevention</subject><subject>vaccine</subject><subject>viral diversity</subject><issn>0732-0582</issn><issn>1545-3278</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqVkU9P3DAQxS3Uil0oX6HKpRIX0_G_JD5QaUFtWWkFHApXy3EcapTYi70B0U-PV1kQHHuaw7x572l-CH0jcEIIL79r78doH7EbhtGHHkMNlEgMlJVU7qE5EVxgRqv6E5pDxSgGUdMZOkjpHgAkY9U-mjHKOIiqnKPFrTbGeZsK7dviLAbd9s_FpR03Uffun_N3xcJvXBNalzVdiMXF8haT4jp3sHkR_Bf0udN9ske7eYhufv38c36BV1e_l-eLFdaihA2uOCMgWtmYuuNdS0vR8IYTUxtiZa1z_Y4IsKSRjFeGArXQkho61lDbiZayQ_Rj8l2PzWBbk9NzRbWObtDxWQXt1MeNd3_VXXhUFasEE1uD451BDA-jTRs1uGRs32tvw5gUZVKUlEshs_R0kpoYUoq2e4shoLYY1A6D2mFQEwY1Ycj3X993fbt-_XsWnE2CrY_us5OzT-k_U14AY9mgoQ</recordid><startdate>20200426</startdate><enddate>20200426</enddate><creator>Stephenson, Kathryn E</creator><creator>Wagh, Kshitij</creator><creator>Korber, Bette</creator><creator>Barouch, Dan H</creator><general>Annual Reviews</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200426</creationdate><title>Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention</title><author>Stephenson, Kathryn E ; Wagh, Kshitij ; Korber, Bette ; Barouch, Dan H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a560t-743105d9bc8f4fd265b4b41c8c1e98a236f150e1b9347c202e0d180f3b2ef5d23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>bNAb</topic><topic>broadly neutralizing antibody</topic><topic>HIV-1</topic><topic>prevention</topic><topic>vaccine</topic><topic>viral diversity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stephenson, Kathryn E</creatorcontrib><creatorcontrib>Wagh, Kshitij</creatorcontrib><creatorcontrib>Korber, Bette</creatorcontrib><creatorcontrib>Barouch, Dan H</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annual review of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stephenson, Kathryn E</au><au>Wagh, Kshitij</au><au>Korber, Bette</au><au>Barouch, Dan H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention</atitle><jtitle>Annual review of immunology</jtitle><addtitle>Annu Rev Immunol</addtitle><date>2020-04-26</date><risdate>2020</risdate><volume>38</volume><issue>1</issue><spage>673</spage><epage>703</epage><pages>673-703</pages><issn>0732-0582</issn><eissn>1545-3278</eissn><abstract>Development of improved approaches for HIV-1 prevention will likely be required for a durable end to the global AIDS pandemic. Recent advances in preclinical studies and early phase clinical trials offer renewed promise for immunologic strategies for blocking acquisition of HIV-1 infection. Clinical trials are currently underway to evaluate the efficacy of two vaccine candidates and a broadly neutralizing antibody (bNAb) to prevent HIV-1 infection in humans. However, the vast diversity of HIV-1 is a major challenge for both active and passive immunization. Here we review current immunologic strategies for HIV-1 prevention, with a focus on current and next-generation vaccines and bNAbs.</abstract><cop>United States</cop><pub>Annual Reviews</pub><pmid>32340576</pmid><doi>10.1146/annurev-immunol-080219-023629</doi><tpages>31</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0732-0582
ispartof Annual review of immunology, 2020-04, Vol.38 (1), p.673-703
issn 0732-0582
1545-3278
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7375352
source Annual Reviews Complete A-Z List
subjects bNAb
broadly neutralizing antibody
HIV-1
prevention
vaccine
viral diversity
title Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A22%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vaccines%20and%20Broadly%20Neutralizing%20Antibodies%20for%20HIV-1%20Prevention&rft.jtitle=Annual%20review%20of%20immunology&rft.au=Stephenson,%20Kathryn%20E&rft.date=2020-04-26&rft.volume=38&rft.issue=1&rft.spage=673&rft.epage=703&rft.pages=673-703&rft.issn=0732-0582&rft.eissn=1545-3278&rft_id=info:doi/10.1146/annurev-immunol-080219-023629&rft_dat=%3Cproquest_pubme%3E2395624959%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2395624959&rft_id=info:pmid/32340576&rfr_iscdi=true